Xsensio, a Swiss digital health company, has secured $7.0 million in its latest funding round. The capital infusion will support the company's continued development and expansion of its unique Lab-on-Skinâ„¢ sensing platform. Xsensio specializes in monitoring early warning signs of health changes by sensing real-time biochemical information at the surface of the skin. This minimally-invasive technology provides continuous, unprecedented data for health and wellness insights.
The Lab-on-Skinâ„¢ platform is designed for next-generation wearables, offering a B2B solution primarily for remote patient monitoring, both at home and in hospital settings. By enabling real-time biochemical analysis directly from the skin, Xsensio aims to provide healthcare professionals with critical data to track patient health and detect potential issues proactively. This approach represents a significant step in personalized and preventative health management.
This $7.0 million investment underscores investor confidence in Xsensio's innovative technology and its potential to transform digital health monitoring. The company plans to strategically deploy the newly acquired funds to accelerate research and development efforts, scale its manufacturing capabilities, and expand its market reach. A key focus will be on enhancing the Lab-on-Skinâ„¢ platform's capabilities and integrating it into a wider array of healthcare applications.
With this funding, Xsensio is positioned to further solidify its presence in the digital health sector. The company anticipates leveraging this capital to drive significant growth, foster strategic partnerships, and ultimately bring its advanced sensing solutions to a broader range of healthcare providers and patients globally, contributing to more effective and proactive health management.
.png&w=3840&q=75)
